Overview
Private hospital operator with multi-specialty centres and diagnostics. The group has repaired profitability at the P&L level but earnings remain thin because finance costs keep taking a large share of operating profit. Balance sheet leverage and liquidity look tight, so the task now is protecting margin gains while easing the interest burden.
Price performance
Measured at LKR 13.50 as of 2026-08-07, NHL rose 112.5% over 1 year versus the ASPI’s 9.5%, but fell 9.9% over 3 months versus the index’s -7.1%. The share sits 19.5% below its 52‑week high, after a strong run that leaves it in the upper third of its range.
Valuation
NHL trades at 14.53x trailing earnings and 3.05x book versus healthcare medians of 11.14x and 1.56x, respectively. The dividend yield is 0.0% against the sector’s 6.7%, and there is no disclosed payout trend in the history provided. With ROE only 1.1%, the current P/B looks stretched unless returns rise meaningfully.
News and sentiment
Direct coverage is thin: 1 material article in the last 90 days, and it was positive. There are no confirmed or pending corporate actions in the dataset.
Financials
Latest quarter to 2026-03-31: margins moved mixed year-on-year. Gross margin was 55.6% vs 54.9% a year ago, operating margin narrowed to 16.6% from 22.9%, and net margin edged down to 4.7% from 5.0%.
Operating execution remained solid but profits were capped below the operating line, consistent with the finance cost burden seen in recent prints. For FY2025 the company turned profitable but at a low level (net margin 0.5%) and ROE was 1.1%, so the repair is not yet translating into robust returns.
Risks
The primary risk is the capital structure: gearing is 136% of owners’ equity and interest cover is 1.09x, leaving little room for shocks if operating profit softens. Liquidity is tight with a 0.32 current ratio, which can constrain working capital and capex flexibility. Market risk is elevated too, with a high ASPI beta of 2.46. Cash conversion was reasonable at 1.12x in FY2025, but this needs to persist to de‑risk the balance sheet.
Outlook
As at 2026-08-07 the next filing (quarter to 2026-06-30) is due now, expected between 2026-07-28 and 2026-10-26. That set will show whether operating margins can hold while the interest burden eases or persists; with rates drifting down in the backdrop, finance costs are the swing factor to watch in the print.